To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
8,327 Current news from the industry pharmarss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Affinity Biosciences antibody binding to the SARS-CoV-2 virus spike protein
Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, announced the discovery of potent antibodies with therapeutic potential against COVID-19.. In March, Affinity commenced screening its proprietary library of one ...
Efforts to manufacture the leading candidates, at risk, are gearing up
Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...
Newly designed ligands for a catalytic reaction to synthesize drugs and useful compounds
Currently, various therapeutic compounds in the market, such as proteins, enzymes, and amino acids, are "chiral compounds"--molecules with two structures that are "mirror" images of each other but cannot be superimposed. Although the two variants of the molecule, also called "enantiomers," are ...
The private placement includes an investment in ordinary shares and a investment in 4-year mandatory convertible notes
BioNTech SE announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. The private placement includes an investment of approximately USD 139 million in ordinary shares and a USD 112 million investment in 4-year mandatory convertible notes. “We ...
The protease protein is both shaped like a heart and functions as one, allowing the virus to replicate and spread
A team of researchers at the Department of Energy's Oak Ridge and Argonne national laboratories has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease -- the enzyme that enables the virus to reproduce. The X-ray measurements mark an important first step in the ...
Turning alcohol into key ingredients for new medicines
Chemists have found a way to turn alcohol into amino acids, the building blocks of life. In a study published in the journal Nature Chemistry, researchers explained the transformation, which involves selectively identifying and replacing molecular bonds with unprecedented precision. The finding ...
First clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of Covid-19 infection
Merck announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 ...
A project studies specific forms of coronavirus parasites to interfere with the replication capacity of SARS-CoV-2 and promote its elimination
A team of researchers from the Spanish National Research Council (CSIC) is leading a project to develop antiviral drugs to prevent the replication of the SARS-CoV-2 coronavirus, which caused the Covid-19 pandemic. The study focuses on the so-called DIPs (Defective Interfering Particles), a common ...
Molecular Containers for the Sequestration of Neurotransmitter Drugs in Water
Molecular containers that remove drugs, toxins, or malodorous substances from the environment are called sequestering agents. Scientists have developed a class of molecular containers that specifically sequester neurotransmitter antagonists. The barrel-shaped molecules called Pillar[n]MaxQ bind ...
Trial will start promptly and will be conducted in Germany and Belgium
CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and ...